Antibody-drug Conjugate for Cancer market

Antibody-drug Conjugate for Cancer Market, Global Outlook and Forecast 2022-2028

  • 25 April 2022
  • Life Sciences
  • 60 Pages
  • Report code : PMR-7018806

  • 4.7 (158)

Antibody-drug Conjugate for Cancer Market

Download FREE Report Sample

  Download Free sample

Antibody-Drug Conjugates (ADCs) are a new class of highly potent biological drugs built by attaching a small molecule anticancer drug or another therapeutic agent to an antibody, with either a permanent or a labile linker. The antibody targets a specific antigen only found on target cells.

Antibody-drug Conjugate for Cancer Market contains market size and forecasts of Antibody-drug Conjugate for Cancer in Global, including the following market information:

  • Global Antibody-drug Conjugate for Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
  • Global top five companies in 2021 (%)

The global Antibody-drug Conjugate for Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Hematological Malignancies Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antibody-drug Conjugate for Cancer include Gilead Sciences, Roche, Pfizer, Takeda, Seagen, Innate Pharma, AstraZeneca, GSK and Rakuten Medical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antibody-drug Conjugate for Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antibody-drug Conjugate for Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Antibody-drug Conjugate for Cancer Market Segment Percentages, by Type, 2021 (%)

  • Hematological Malignancies Drugs
  • Solid Tumor Drugs

Global Antibody-drug Conjugate for Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Antibody-drug Conjugate for Cancer Market Segment Percentages, by Application, 2021 (%)

  • Hospital
  • Pharmacy
  • Other

Global Antibody-drug Conjugate for Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Antibody-drug Conjugate for Cancer Market Segment Percentages, By Region and Country, 2021 (%)

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Nordic Countries
  • Benelux
  • Rest of Europe
  • Asia
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Rest of Asia
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East & Africa
  • Turkey
  • Israel
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

  • Key companies Antibody-drug Conjugate for Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
  • Key companies Antibody-drug Conjugate for Cancer revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

  • Gilead Sciences
  • Roche
  • Pfizer
  • Takeda
  • Seagen
  • Innate Pharma
  • AstraZeneca
  • GSK
  • Rakuten Medical

CHECK TODAYS BEST PRICE

BEST PRICE: $2275
Buy Full Report

Select Licence type with your requirement and needs

SECURITY ASSUREDpayment image

analyst icon
Still not found what you want?

Speak to our Custom Research Team and get the Custom Research in a budget

Custom Research


Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

WHY CHOOSE US

  • Proactive We manage our resources 24/7 to identify issues and address them before they become problems
  • Quality & Reliability We are committed to providing reliable and highly accurate data with an excellent quality control system
  • Global Outreach 6 Major regions and 40+ countries level analysis accomplished
  • Competitive Pricing Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

SAMPLE REPORT INCLUDES
  • Industry Market SizeIndustry Market Size
  • SWOT AnalysisSWOT Analysis
  • Industry Major PlayersIndustry Major Players
  • Revenue ForecastsRevenue Forecasts
  • Historical and Forecast GrowthHistorical and Forecast Growth
  • Profitability AnalysisProfitability Analysis
SOME OF OUR CLIENTS
WHAT SET US APART?
  • quilty

    Quality Assurance

    Focus on Data Accuracy & Reliability
  • quilty

    Trusted by the Best

    75+ Clients in Fortune 500
  • quilty

    Privacy and Security

    All your transactions are secured end-to-end, ensuring a satisfactory purchase
  • quilty

    Competitive Pricing

    Ensure the best and affordable pricing
OUR HAPPY CUSTOMER Some of our customer review
Stay Updated About Antibody-drug Conjugate for Cancer Market

Leave This Empty: